文献速递乳腺癌

基于DESTINY-Breast03试验二次利用的曲妥珠单抗德鲁替康对比曲妥珠单抗恩坦辛在HER2阳性转移性乳腺癌患者中的质量调整无症无毒性生存时间分析

Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
PubMed 文献 · Eur J Cancer · 2024-12-26

基于DESTINY-Breast03随机3期试验的二次分析,采用Q-TWiST方法比较T-DXd与T-DM1在HER2阳性不可切除和/或转移性乳腺癌患者中的治疗差异。T-DXd较T-DM1在Q-TWiST上显示出具有临床意义的改善(平均差异=3.80个月,95%CI:[1.91, 5.62],名义P值<0.001;相对增益=11.64%),阈值效用分析支持结果稳健性。结论认为T-DXd在考虑治疗暴露时间后改善了质量调整无症无毒性生存时间,显示其改善生存长度和生活质量。

要点

  • T-DXd较T-DM1的Q-TWiST平均差异为3.80个月(95%CI:1.91–5.62,名义P值<0.001)。
  • 相对增益为11.64%,阈值效用分析支持结果稳健性。
  • 结论认为T-DXd在考虑治疗暴露时间后改善质量调整无症无毒性生存时间。

核心结论

  • T-DXd较T-DM1在质量调整无症无毒性生存时间上产生实质性改善,显示其改善生存长度和生活质量。

研究设计与样本

  • 基于DESTINY-Breast03随机3期试验的二次利用分析,纳入HER2阳性不可切除和/或转移性乳腺癌患者,这些患者在曲妥珠单抗和紫杉烷治疗中或之后进展。
  • 将患者生存数据分为三个健康状态:3-4级不良事件时间(TOX)、疾病进展前无不良事件时间(TWiST)和疾病进展至死亡时间(PROG)。
  • 以EQ-5D-5L问卷中各健康状态的平均效用评分加权平均健康状态持续时间并求和得到Q-TWiST值,并进行阈值效用分析。

主要发现

  • T-DXd较T-DM1的Q-TWiST平均差异=3.80个月(95%CI:[1.91, 5.62],名义P值<0.001;相对增益=11.64%)。
  • 阈值效用分析支持结果的稳健性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: DESTINY-Breast03, a randomised, phase 3 trial, evaluated trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor (HER2)-positive unresectable and/or metastatic breast cancer who progressed on or after treatment with trastuzumab and a taxane. At the current data cut off overall survival analysis, T-DXd demonstrated a substantial improvement in overall survival over T-DM1. This secondary analysis use of DESTINY-Breast03 aimed to further evaluate the treatment differences using quality-adjusted survival time without symptoms or toxicity (Q-TWiST) methods. METHODS: Patients' survival data was divided into three health states: time spent with grade 3-4 adverse events (TOX), time without adverse events before disease progression (TWiST), and time from disease progression to death (PROG). Mean health state duration was weighted by patients' mean utility score in each health state based on the EQ-5D-5L questionnaire and summed to obtain the Q-TWiST value. A threshold utility analysis was also conducted using a range of hypothetical utility scores to assess the impact on Q-TWiST values obtained. RESULTS: T-DXd was associated with a substantial and clinically important improvement in Q-TWiST compared to T-DM1 (mean difference = 3.80 months, 95 % CI: [1.91, 5.62], nominal P-value <0.001; relative gain = 11.64 %). The robustness of the results was supported by threshold utility analysis. CONCLUSION: T-DXd produced a substantial improvement in quality-adjusted time without symptoms or toxicity when accounting for time on treatment exposure compared to T-DM1. Consequently, T-DXd is shown to improve both length and quality of life.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dennis N, Dunton K, Livings C, et al. Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. Eur J Cancer. 2024. PMID: 39798264. doi:10.1016/j.ejca.2024.115192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。